Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Medinger

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Annals of Hematology|March 28, 2019
Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center studyYves Soltermann, Dominik Heim, Michael Medinger, et al.
Bone Marrow Transplantation|August 13, 2024
Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantationMarie Janscak, Anne Stelmes, Jana van den Berg, et al.
Bone Marrow Transplantation|February 28, 2019
Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantationAnnic Baumgartner, Michèle Moesch, Melanie Zumsteg, et al.
Journal for Immunotherapy of Cancer|December 1, 2022
Dasatinib for treatment of CAR T-cell therapy-related complicationsKatharina Baur, Dominik Heim, Astrid Beerlage, et al.
Annals of Hematology|December 14, 2018
Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantationMonica Bianchi, Dominik Heim, Claudia Lengerke, et al.
Swiss Medical Weekly|May 15, 2024
Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugsDominik Heim, Helen Baldomero, Michael Medinger, et al.
In Vivo (Athens, Greece)|November 4, 2020
New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell TransplantationVera Dalla Via, JÖrg P Halter, Sabine Gerull, et al.
Hematology (Amsterdam, Netherlands)|October 1, 2013
Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantationSara C Meyer, Michael Medinger, Jörg P Halter, et al.
Anticancer Research|July 24, 2010
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancerJoachim Drevs, Michael Medinger, Klaus Mross, et al.
Bone Marrow Transplantation|August 16, 2018
High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host diseaseSarah Kraft, Noémie Bollinger, Benjamin Bodenmann, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Annals of Hematology|March 28, 2019
Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center studyYves Soltermann, Dominik Heim, Michael Medinger, et al.
Bone Marrow Transplantation|August 13, 2024
Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantationMarie Janscak, Anne Stelmes, Jana van den Berg, et al.
Bone Marrow Transplantation|February 28, 2019
Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantationAnnic Baumgartner, Michèle Moesch, Melanie Zumsteg, et al.
Journal for Immunotherapy of Cancer|December 1, 2022
Dasatinib for treatment of CAR T-cell therapy-related complicationsKatharina Baur, Dominik Heim, Astrid Beerlage, et al.
Annals of Hematology|December 14, 2018
Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantationMonica Bianchi, Dominik Heim, Claudia Lengerke, et al.
Swiss Medical Weekly|May 15, 2024
Allogeneic haematopoietic cell transplantation for chronic myeloid leukaemia in Switzerland in the face of rapid development of effective drugsDominik Heim, Helen Baldomero, Michael Medinger, et al.
In Vivo (Athens, Greece)|November 4, 2020
New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell TransplantationVera Dalla Via, JÖrg P Halter, Sabine Gerull, et al.
Hematology (Amsterdam, Netherlands)|October 1, 2013
Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantationSara C Meyer, Michael Medinger, Jörg P Halter, et al.
Anticancer Research|July 24, 2010
A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancerJoachim Drevs, Michael Medinger, Klaus Mross, et al.
Bone Marrow Transplantation|August 16, 2018
High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host diseaseSarah Kraft, Noémie Bollinger, Benjamin Bodenmann, et al.
Pageof 9